

CLAIMS

1. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an
5 antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
2. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an
10 anti-cancer effect in a warm-blooded animal such as a human.
3. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.
15
4. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
20
5. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
25
6. Use of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
30
7. Use according to any one of claims 1-6 wherein AZD2171 is in a form of the free base.
8. Use according to any one of claims 1-7 wherein the taxane is paclitaxel.

9. Use according to any one of claims 1-7 wherein the taxane is docetaxel.
10. A pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, and a taxane in association with a pharmaceutically acceptable excipient or carrier.
11. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof and a taxane.
- 10 12. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane.
- 15
13. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof excluding an AZD2171 maleate salt, before, after or simultaneously with an effective amount of a taxane and before, after or simultaneously with an effective amount of ionising radiation.
- 20
14. A method according to claim 12 or claim 13 wherein AZD2171 is in a form of the free base.
- 25 15. A method according to any one of claims 12-14 wherein the taxane is paclitaxel.
16. A method according to any one of claims 12-14 wherein the taxane is docetaxel.